Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Barclays Maintains Equal-Weight on Pfizer, Lowers Price Target to $44

Barclays analyst Carter Gould maintains Pfizer (NYSE:PFE) with a Equal-Weight and lowers the price target from $50 to $44.
byBenzinga Newsdesk
October 12, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Barclays analyst Carter Gould maintains Pfizer (NYSE:PFE) with a Equal-Weight and lowers the price target from $50 to $44.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0